Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer

This is mostly a low-cost pipeline option for MRK, not a near-term earnings driver. The market should treat the collaboration as a way to extend KEYTRUDA relevance in GI tumors that are otherwise hard to immuno-enable, but the economic value only matters if the combo produces cleaner durability than existing chemo/IO backbones. Until then, any move in MRK should be modest and largely sentiment-driven rather than fundamentals-driven.

The more interesting second-order effect is on the CLDN18.2/CD47 ecosystem: if this class shows tolerable hematologic safety, it can re-rate a basket of adjacent GI immuno-oncology names and make Merck a more attractive partner of choice. The contrarian risk is that CD47 biology has repeatedly looked better in theory than in clinic; a small amount of anemia/thrombocytopenia would be enough to cap enthusiasm and compress multiples across the space.

Timing matters: immediate impact on MRK is negligible, while the real catalyst path is 3-6 months for enrollment/safety signals and 12-18 months for any efficacy read-through. The thesis is falsified if dose intensity is poor, if Merck does not continue expanding the program beyond a narrow collaboration, or if early BTC data fail to separate from historical response rates. In that case, the announcement becomes a standard BD press release rather than a platform validation event.